The interaction between alcohol consumption and metabolic dysfunction has likewise come into sharper focus. A large longitudinal analysis conducted in the United States showed that binge drinking combined with metabolic risk factors substantially contributes to the progression of steatotic liver disease and significantly increases the risk of advanced liver disease (Younossi et al.). Complementing these findings, the European LiverScreen study revealed that the prevalence of clinically relevant liver fibrosis in the general population is considerably higher than previously assumed. In many cases, fibrosis remains undiagnosed and is closely associated with both metabolic dysfunction and alcohol-related risk factors (Graupera et al.). Against this backdrop, early identification of at-risk patients is becoming increasingly significant.

Novel diagnostic approaches may help address this unmet need. For example, the MetALD-ALD Prediction Index, a phosphatidylethanol (PEth)-based biomarker algorithm that improves the identification of patients with steatotic liver disease while simultaneously detecting increased alcohol consumption (Tavaglione et al.). PEth may also prove valuable for prognostic assessment: In another study, combining PEth measurements with non-invasive fibrosis procedures significantly improved prediction of clinical outcomes in alcohol-associated liver disease (Torp et al.). These developments underscore the potential of serum-based markers for diagnostics, risk stratification, and treatment monitoring.

Therapeutic advancements are equally encouraging. A recent study demonstrated that in patients with severe alcohol withdrawal syndrome and alcohol-associated liver disease in the intensive care unit, phenobarbital showed safety and efficacy comparable to that of benzodiazepines, suggesting it may represent an additional treatment option in the future (Govalan et al.). Furthermore, pharmacological treatment of alcohol use disorder is receiving increasing attention in hepatological research. In a randomized, placebo-controlled trial, once-weekly treatment with semaglutide in patients with alcohol use disorder and obesity significantly reduced alcohol consumption while also producing favorable metabolic effects (Kruse Klausen et al.). These findings may open new therapeutic perspectives, especially for patients with metabolic dysfunction- and alcohol-associated liver disease.

Taken together, the studies presented in this issue impressively demonstrate the close interplay between alcohol, metabolic dysfunction, and chronic liver disease. At the same time, they highlight the considerable progress being made in both diagnostics and therapeutics, providing reason for optimism that earlier detection and more effective treatment of alcohol-associated liver disease may become increasingly achievable. This is clearly a field to watch, and we look forward to reporting on future advances.

Yours sincerely,

Peter Hasselblatt and Tobias Böttler
Department of Internal Medicine II, University Medical Center Freiburg (Germany)